Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. - Wikidata - wikimedia - TriplyDB

Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.

Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.

http://www.wikidata.org/entity/Q33780751

about

Targeted anti-vascular therapies for ovarian cancer: current evidence Combinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current status The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis.Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer Differential post-surgical metastasis and survival in SCID, NOD-SCID and NOD-SCID-IL-2Rγ(null) mice with parental and subline variants of human breast cancer: implications for host defense mechanisms regulating metastasis.Combination metronomic oral topotecan and pazopanib: a pharmacokinetic study in patients with gynecological cancer.Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program.The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma.Reappraising antiangiogenic therapy for breast cancer.Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.Drug rechallenge and treatment beyond progression--implications for drug resistance.Development of Patient Derived Xenograft Models of Overt Spontaneous Breast Cancer Metastasis: A Cautionary Note Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models.Bevacizumab and ovarian cancer Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer.Targeting of topoisomerases for prognosis and drug resistance in ovarian cancer.Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma Controlling escape from angiogenesis inhibitors.Clinical response in patients with ovarian cancer treated with metronomic chemotherapy.Metronomics: towards personalized chemotherapy?The emerging quest for the optimal angiostatic combination therapy.Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy.Overview of fundamental study of pazopanib in cancer.Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib.CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer.Synergistic antitumor effect of combining metronomic chemotherapy with adoptive cell immunotherapy in nude mice.Microscopic Modes and Free Energies for Topoisomerase I-DNA Covalent Complex Binding with Non-campothecin Inhibitors by Molecular Docking and Dynamics Simulations.Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALKF1174L Drug-Resistant Neuroblastoma Preclinical Models.Metabolic behavior prediction of pazopanib by cytochrome P450 (CYP) 3A4 by molecular docking.Tumor dynamics in response to antiangiogenic therapy with oral metronomic topotecan and pazopanib in neuroblastoma xenografts.Metronomic chemotherapy for triple negative breast cancer?Low-dosage metronomic chemotherapy and angiogenesis: topoisomerase inhibitors irinotecan and mitoxantrone stimulate VEGF-A-mediated angiogenesis.EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming.Immunotherapeutic Targeting of Tumor-Associated Blood Vessels.Discontinuous Schedule of Bevacizumab in Colorectal Cancer Induces Accelerated Tumor Growth and Phenotypic Changes.

P2860

Q26830287-F4389F9B-8050-4CE6-A1C4-F35BF3F15D30 Q27001560-7F0BE31D-83AA-4623-9C70-52AE3A6E4F68 Q28744228-F1FDA47E-D064-4906-B7B1-C5B84AB8DAF5 Q30523830-61762A87-2FC1-46E7-9942-D7877CF8E853 Q33728605-91C30693-1F1B-4EBB-B6BC-581A80A74375 Q33875597-78933350-8595-451D-8760-F34BFEC4FBD5 Q34963659-734AD402-CE1E-4A8E-A672-036234CF2F51 Q35282945-F8E1F8CB-9CFF-48C3-A203-377A5E817F72 Q35659433-1AD97AB4-D7D9-419C-A63D-BFB266E2E14B Q35793799-51D6679B-D267-40A6-8900-07AAFBE6E5CE Q35966766-44EF6984-EBD2-4B19-B9F5-9FC09AEDD687 Q35966821-800E5318-01F6-4586-BF98-2DE683A54401 Q35967416-4AD46707-3969-40D5-92BA-386AA4A60B72 Q36063937-F3219300-980E-43E7-8973-1ACCBD04C7F9 Q36237312-9366DE52-0FC4-429A-AE3D-E4C039CA0263 Q36359684-0744F365-E80E-4B82-AE7B-2CF3E7C8A833 Q36557707-7539F23D-81A4-40D1-83FA-8DB801497821 Q36567390-33C5AD05-9455-46AE-85F1-18689409A216 Q36618871-DC264C1C-6757-403E-8D2B-B163BB5AD197 Q37018096-A6D31F2C-2CEE-4292-A416-A19CBC78C8C9 Q37236004-8B46ECE7-B31E-4AEA-81EC-D700BFDDCCE4 Q37672654-1C80404D-BBA6-4B2C-B4B9-71F2B81D3DC7 Q37679904-9C52622A-DD3E-43F6-828E-40E60A6BFC2C Q38218923-6150818A-EB9A-467F-99A2-B2568CE411CD Q38268453-B85AD923-D2A5-4495-B2AC-63368D69DDE0 Q38489591-2A637231-D501-47CB-BD2B-91C359EC5D93 Q38696525-E51DE4D7-15A6-44C4-A118-A8ABEADB09F7 Q38889516-24461C7E-C891-4CA4-A5DC-187A0DFFCF02 Q38891812-E5714DD4-FF2A-4B22-AA76-3543D5BB2EC1 Q39015610-C9A4970C-9385-4723-B4C6-D906F30F18E0 Q39289157-AED9C940-CC44-4FBB-9782-99C1FFC1C5F8 Q39501053-DF4D2352-2055-4B33-B685-AD85ECEADA45 Q40999620-9CDDC701-C040-43F7-B3F8-C769736D8454 Q41304112-CA9EBD20-6D42-409F-A593-4561771CF7D1 Q41912972-5E2645C0-5DF3-462C-9756-5DF403C4D713 Q42523304-FBD400A9-7593-476A-9B5E-E46FD74CE09A Q42554491-932115B9-E478-407A-895D-3DE68BDC3487 Q47600932-0DDD9AC5-99D7-4229-AC51-BDC4A83FF0D3 Q49592831-C3FD230A-9373-4AD6-809B-C6027A7AAC98 Q49833366-2E9BDFAA-20F1-4B28-A394-8249ACF8A8B4

P2860

Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.

http://www.wikidata.org/entity/Q33780751

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Potent preclinical impact of m ...... e treatment of ovarian cancer.

@ast

Potent preclinical impact of m ...... e treatment of ovarian cancer.

@en

type

label

Potent preclinical impact of m ...... e treatment of ovarian cancer.

@ast

Potent preclinical impact of m ...... e treatment of ovarian cancer.

@en

prefLabel

Potent preclinical impact of m ...... e treatment of ovarian cancer.

@ast

Potent preclinical impact of m ...... e treatment of ovarian cancer.

@en

P1433

Q33780751-50480AD4-E119-49DC-86F6-4ACE25736936

P1476

Q33780751-FDEAFE0C-B6EE-4B16-B626-43EE59592EB6

P2093

Q33780751-0F79894F-F1B7-46DA-9F02-CCD0CD5AC314

Q33780751-10474253-1D93-4448-ABF5-221C941ED47D

Q33780751-2948AB78-4295-4B34-ACDB-14D031157C54

Q33780751-39F9EDC9-F76B-4EFE-BD14-AD6B612DCD7C

Q33780751-404F023D-9E1D-408C-A019-F62930DAB626

Q33780751-9E1348C0-7673-4326-8569-AA1DB906F006

Q33780751-D1BEF27E-274B-43E6-AD89-F61E6EF72427

P2860

Q33780751-05BCD0FA-7B71-4329-B874-6A26C494CF3B

Q33780751-0BD9CA64-B95F-464F-A931-175F4FF4E217

Q33780751-1000C6D5-462F-4C22-9186-4ED68AB0DA9E

Q33780751-10287DCF-428E-439C-97BE-78B1D943261D

Q33780751-125E17BD-3887-45D3-B55F-770DABB466FE

Q33780751-13FB37A0-B397-4586-A611-BEC42ED2D65B

Q33780751-1663DE4C-9B25-4354-BB51-26919D666F45

Q33780751-192FCED5-0161-46C5-A264-0956E6BBBE67

Q33780751-23616762-4DCD-4DBE-8D5F-659137072C5A

Q33780751-26966B66-17DC-49EB-B74F-F19AC14ABAC4

P304

Q33780751-00B3750D-38A1-4183-8395-0F583D2E6CB2

P31

Q33780751-E71446C8-58CB-4BB9-A1AA-C3EC44373F34

P356

Q33780751-DD462758-3C19-428E-BA96-1FDB8417E584

P433

Q33780751-BDE39C31-71EF-433A-AA74-B4D756B22DAF

P478

Q33780751-A0A5250A-E410-4A6D-82E4-9C7E0AF91B3C

P577

Q33780751-2A5A77AC-314A-4053-A6F4-5A926D2959A2

P698

Q33780751-77FB483B-F1E5-4163-8533-E41279A87924

P921

Q33780751-B0E8734D-6637-4FE1-AF0B-1B365C03254C

P932

Q33780751-51EF55A7-7115-4691-9237-94A298801D4C

P356

1535-7163.MCT-09-0960

P1433

Molecular Cancer Therapeutics

P1476

Potent preclinical impact of m ...... e treatment of ovarian cancer.

@en

P2093

Kae Hashimoto

http://www.w3.org/2001/XMLSchema#string

Ping Xu

http://www.w3.org/2001/XMLSchema#string

Rakesh Kumar

http://www.w3.org/2001/XMLSchema#string

Robert S Kerbel

http://www.w3.org/2001/XMLSchema#string

Shan Man

http://www.w3.org/2001/XMLSchema#string

Terence Tang

http://www.w3.org/2001/XMLSchema#string

William Cruz-Munoz

http://www.w3.org/2001/XMLSchema#string

P2860

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivo detection of mammary tumors and multiple metastases in immune deficient mice

Targeting HIF-1 for cancer therapy

Ovarian surface epithelium: biology, endocrinology, and pathology

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.

Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells

P304

996-1006

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-09-0960

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2010-04-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20371722

http://www.w3.org/2001/XMLSchema#string

P921

P932

2852477

http://www.w3.org/2001/XMLSchema#string